scispace - formally typeset
N

Nieves Basterreche

Researcher at University of the Basque Country

Publications -  25
Citations -  158

Nieves Basterreche is an academic researcher from University of the Basque Country. The author has contributed to research in topics: Bipolar disorder & Homovanillic acid. The author has an hindex of 7, co-authored 24 publications receiving 136 citations.

Papers
More filters
Journal ArticleDOI

GABA and homovanillic acid in the plasma of Schizophrenic and bipolar I patients.

TL;DR: The values of the ratio pHVA/pGABA are compatible with the idea of an abnormal dopamine-GABA interaction in schizophrenic and bipolar patients and may be a good peripheral marker in psychiatric research.
Journal ArticleDOI

Catechol O-methyltransferase and monoamine oxidase A genotypes, and plasma catecholamine metabolites in bipolar and schizophrenic patients.

TL;DR: The results suggest that this Val158Met polymorphism, alone or associated with other polymorphisms, could have an important role in the genetic control of monoamine concentration and its metabolites.
Journal ArticleDOI

Influence of the catechol-O-methyltransferase Val108/158Met polymorphism on the plasma concentration of catecholamine metabolites and on clinical features in type I bipolar disorder- : A preliminary report

TL;DR: The Val108/158Met polymorphism does not appear to be a crucial determinant in type I bipolar disorder and a non-significant aggregation of bipolar patients presenting with psychosis was found in the homozygous Val-Val group.
Journal ArticleDOI

The Influence of the Val158Met Catechol-O-Methyltransferase Polymorphism on the Personality Traits of Bipolar Patients

TL;DR: Suffering from bipolar disorder could have an impact on personality; a greater value in harm avoidance may be a genetic marker for a vulnerability to the development of a psychiatric disorder, but not bipolar disorder particularly, while a low value in persistence may characterize affective disorders or a subgroup of bipolar patients.
Journal Article

Aripiprazole reverses paliperidone-induced hyperprolactinemia.

TL;DR: A clinical case of a female patient in whom the combined treatment of 5 mg/day of aripiprazole (5 mg/ day) reversed paliperidoneinduced hyperprolactinemia within four weeks is reported.